Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPA dose-finding trial in knee osteoarthritis
2023-508791-11-00Phase 2Completed
- Sponsor
- AKL Research & Development Limited
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of APPA, apocynin and paeonol in knee osteoarthritis (OA) (2 arms), sponsored by AKL Research & Development Limited. Primary endpoint: Change from baseline in WOMAC pain sub-score. Started Apr 2024; status: completed.
02
Drugs
APPAapocyninpaeonol
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2023-508791-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508791-11-00.